stars 1 stars 2 stars 3

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.

Genelabs Technologies Questions

The Genelabs Technologies annual revenue was $18 million in 2026.

Fred Driscoll is the CEO of Genelabs Technologies.

10 people are employed at Genelabs Technologies.

Genelabs Technologies is based in Redwood City, California.

The NAICS codes for Genelabs Technologies are [32, 3254, 32541, 325].

The SIC codes for Genelabs Technologies are [283, 28].

Top Genelabs Technologies Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users